Matinas BipPharma secures enrollment for MAT9001 head-to-head trial versus Vascepa

Matinas BipPharma Holdings Inc (NYSEAMERICAN:MTNB) announced Thursday that it completed enrollment of a head-to-head trial of its drug MAT9001 against Vascepa in a battle to lower triglycerides.

The ENHANCE-IT ((Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia) will evaluate MET9001’s effective in reducing triglyceride levels and other important lipid markets. 

The upcoming study is MAT9001’s second competitive trial against Vascepa, the company said. Topline results are expected in early 2021.

READ: Matinas BioPharma publishes data from Phase 1 EnACT study of MAT2203 to treat cryptococcal meningitis

“Successful completion of ENHANCE-IT enrollment is a key milestone for Matinas, and this study will provide important data for both MAT9001 and Vascepa,” chief medical officer James Ferguson said in a statement. “We believe the data generated in this clinical trial should further differentiate MAT9001’s superior clinical profile over Vascepa.”

EHANCE-IT is an open-label, randomized, four-week crossover study analyzing the pharmacodynamic effects of both drugs in patients with elevated triglycerides. The study will consist of two four-week treatment periods with a washout period of the same length period between treatments.

“The data from ENHANCE-IT will be an important addition to our understanding of the rapidly-growing omega-3 class and help guide the future treatment of patients with cardiovascular disease and elevated triglycerides,” Ferguson said. “The dedication and commitment of the clinical trial sites, the investigators, and the study participants allowed us to complete enrollment in less than three months during an otherwise challenging time.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors